



Arix Bioscience plc

Results of Annual General Meeting

LONDON, 4 June 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing and building breakthrough biotech companies, announces that its Annual General Meeting (the "Meeting") was held today, Thursday, 4 June 2020, at 14.00 BST. At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 4 May 2020 (the "Notice of AGM"), were proposed and passed by way of a poll.

Full details of the poll results are set out below.

No	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	TOTAL VOTES	% of ISC VOTED	VOTES WITHHELD
01	To receive the Directors' report and the accounts for the Company for the year ended 31 December 2019	39,702,307	100.00%	1,111	0.00%	39,703,418	29.29	0
02	To approve the Directors' Remuneration Report for the year ended 31 December 2019	28,565,229	71.98%	11,118,962	28.02%	39,684,191	29.28	19,227
03	To re-elect Professor Trevor Jones as a Director	39,701,337	100.00%	1,757	0.00%	39,703,094	29.29	324
04	To re-elect Giles Kerr as a Director	39,701,633	100.00%	1,111	0.00%	39,702,744	29.29	674
05	To re-elect Mark Breuer as a Director	39,702,744	100.00%	0	0.00%	39,702,744	29.29	674
06	To elect Naseem Amin as a Director	38,002,697	95.72%	1,700,047	4.28%	39,702,744	29.29	674
07	To re-appoint PwC LLP as auditors of the Company	39,693,236	100.00%	1,303	0.00%	39,694,539	29.28	8,879
08	To authorise the Audit & Risk Committee of the Company to fix the remuneration of the auditors	39,694,848	100.00%	970	0.00%	39,695,818	29.28	7,600
09	To authorise the Directors to allot shares	37,991,949	95.69%	1,709,598	4.31%	39,701,547	29.29	1,871
10	To authorise the Directors to disapply statutory pre-emption rights in respect of 5% of the Company's issued share capital*	37,087,210	93.42%	2,613,385	6.58%	39,700,595	29.29	2,823
11	To authorise the Directors to disapply statutory pre-emption rights in respect of an additional 5% of the Company's issued share capital*	37,085,231	93.42%	2,613,385	6.58%	39,698,616	29.29	4,802
12	To authorise the Company to buy back shares*	39,693,090	99.98%	7,878	0.02%	39,700,968	29.29	2,450
13	To authorise the Directors to call a general meeting other than an annual general meeting on not less than 14 clear days' notice*	39,694,818	99.98%	7,079	0.02%	39,701,897	29.29	1,521

* Special resolution

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 12 May 2020, which is available on Arix investor relations website at: <https://arixbioscience.com/investor-relations/events-presentations>.

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

T: +44 (0) 203 922 0891

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

www.arixbioscience.com